STLN 8-K/A 2026-11-12

Starling Oncology, Inc. (STLN) 8-K/A dated 2026-11-12 — accession 0001079973-26-001469.

Starling Oncology, Inc. (STLN) common stock.

Starling Oncology, Inc. filed a 8-K/A on 2026-11-12. Accession 0001079973-26-001469.

This 8-K/A covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported STLN revenue for 2025-12-31 was $502.7M. Net income was -$60.6M. Revenue was up 27.8% from 2024-12-31 to 2025-12-31. STLN currently screens at market cap $382.5M.

Not investment advice. The STLN SEC hub lists recent forms. The stock page is the research view.